Digital Asset DirectJennifer Lang Financial Services, LLC
Contact Details Jennifer Lang Financial Services, LLC. Jennifer Lang +1 877-487-8926 mail@jenniferlangfinancialservices.com Company Website https://www.jenniferlangfinancialservices.com
May 04, 2021 10:05 AM Eastern Daylight Time
Video
News ReleaseCereHealth
CereMetrix Corp., a wholly owned subsidiary of data analytics technology company CereHealth Corp., has released an enhanced version of its imaging platform, CereMetrixAi™. Using its FDA-cleared QSPECT ® analysis as a template, the platform can now incorporate additional imaging, such as MRI, PET and CT, and non-imaging analytical assessments through an expanding catalog of both in-house and third-party medical image algorithms. Its improved integration capabilities for data collection and reporting opens the door for broader use of non-imaging assessments like neuropsychological evaluations and cognitive screens and expands the platform’s clinical and research applications. CereMetrixAi™ is a browser-based, cloud-enabled, HIPAA-compliant imaging platform that features FDA-cleared QSPECT® analysis. The platform offers accessible, automated, and objective imaging to radiologists and treating providers to detect, quantify and analyze in significantly less time than other reading tools, and at significantly less expense than traditional workstation-based software solutions. Now with its open platform architecture, various sources of imaging and non-imaging data can be analyzed in a templated, customizable report that is available to clinicians and their patients anytime, anywhere through a browser. The new release offers efficiency and user experience enhancements to radiologists through inherent support for overreads, customizable templated language fields and a new interface for annotations and image capture. It also allows other medical imaging modalities such as MRI, PET and CT to take advantage of the three-dimensional visualization capabilities that were previously offered solely with SPECT brain studies. Third party imaging developers may now deliver their products to the market via CereMetrixAi’s browser-based platform, expanding the visualization options available and providing doctors a more complete path toward accurate diagnoses. “Our vision of bringing data driven medical imaging and analytics to healthcare professionals worldwide takes a giant leap forward with the introduction of CereMetrix 2.0,” said Shane Quint, Chief Technology Officer of CereHealth Corp. “By integrating all sources and types of patient data in a user-friendly platform we are enabling a more complete picture of an individual’s health for more effective diagnosis and treatment. It is the definition of Precision Medicine, and we are proud to be a leader in software solutions that make sense for patients, providers and researchers at all levels.” Personalized Medicine, matching a specific patient to a similar patient group, will be realized when the entirety of factors affecting a person’s health are considered. Then disease prevention and treatment can be tailored around their unique characteristics. By seamlessly integrating digital health data of all types, CereHealth’s technologies enable medical professionals (and researchers) to advise with precision and accuracy the best diagnostic outcome leading to the right treatment for the right patient at the right time in their lives. About CereHealth CereHealth is a data analytics technology company that provides Medical Analytics as a Service (MAaaS), enabling doctors, research scientists and others serving the healthcare community to quickly make more-informed decisions regarding patient-specific treatments for a higher likelihood of success to improve outcomes and patients’ quality of life. CereHealth is a leader in multivariable analysis of quantitative biomarkers for central nervous system (CNS) disorders with 2 patents on neuroimaging database systems and methods (and 1 patent pending), and a proprietary growing database of more than one million structured patient datapoints that include neuro imaging, cognitive assessments, detailed clinical history, and blood biomarkers. Though our structured database focuses on CNS disorders, our software is not limited to a disease, brain region, or any biomarker. To learn more about CereHealth’s MAaaS solutions, including scheduling a live demonstration visit us at ceremetrix.io. Contact Details CereHealth Corp. Shane Quint, Chief Technology Officer +1 303-282-4702 squint@cerescan.com Company Website https://ceremetrix.io/
May 04, 2021 07:00 AM Mountain Daylight Time
News ReleaseZOE
Healthcare science company ZOE announced today it has raised $53M in total funding to transform how individuals eat with a first-of-its-kind at-home test kit and personalized advice program. ZOE decodes each customer’s unique biological responses to food, and guides them on how to eat to maximize long-term health. The program uses machine learning combined with the world’s largest nutrition research studies. These funds will allow ZOE to meet the dramatic rise in customer demand since it launched a few months ago, and serve millions of people in search of a sustainable and science-backed approach to healthy eating. Addressing high rates of obesity, metabolic disease, and nutritional confusion, ZOE launched its first product in September 2020 after three years in stealth carrying out the world’s largest in-depth nutrition and microbiome study with scientists from Harvard, King’s College London, Mass General Hospital and Stanford. The test kit analyzes users’ gut health, as well as blood fat and blood sugar responses to food and uses these insights to provide daily, personalized nutrition guidance. Demand is high and ZOE is currently in waitlist-mode. Interim clinical trial results reveal participants experienced more energy (90%), felt less hunger (80%) and lost an average of 11 pounds after three months of following their personalized plan. Today’s B round of over $20M brings cash on the balance sheet to $40M. This round of financing is led by Ahren Innovation Capital (“Ahren”), whose Science Partners include two Nobel laureates. Sir Gregory Winter CBE FRS FMedSci and Nobel Prize winner for Chemistry said: “We were interested both by the approach taken by ZOE, in which they are applying machine learning to large scale population data, and by their published results, in which they are mapping out associations between diet, health and the gut microbiome.” Additional participants in this financing include two-time Super Bowl Champion and MVP Eli Manning, two-time Super Bowl Champion and award-winning sportscaster Ositadimma "Osi" Umenyiora, Accomplice (the fund behind AngelList, DraftKings, PillPack, and WHOOP), THVC and Daphni. Umenyiora said, “I'm really excited to invest in ZOE. As an athlete, I know how much eating the right food changes how I feel and how I perform.” The funds from the investment will be used to speed up the rollout of the ZOE program. Currently, the program is only available in the US, but a launch is intended in the UK in 2021 and further geographies in 2022. ZOE is continuing to hire rapidly, including in engineering and science, where its expertise spans from microbiome and nutrition to metabolic research and machine learning. Commenting on the investment, George Hadjigeorgiou, co-founder and President of ZOE, said: "We started ZOE because we believe that everyone has a right to understand how their body responds to food so they can make their own decisions and be in control of their health. We are thrilled to be partnering with a distinguished group of new and existing investors to continue on our mission to help people live healthier and happier lives.” “After 4 years of research and results published in the world’s leading medical journals, we are delighted to accelerate the launch of the ZOE program because we believe people need our help,” said Jonathan Wolf, co-founder and CEO of ZOE. “Ahren Innovation Capital, Eli Manning and Osi Umenyiora’s backing of ZOE further validates the belief held by leaders across diverse industries that we can have a powerful impact on our health through in-depth, personalized insights into our biology.” Science Supported with Multiple Papers Published in Top Peer-Reviewed Journals Experiencing rapid revenue growth and forecasting double-digit millions of revenue in its first year of sales, ZOE uses a data-driven approach to tackling global health issues. The company combines artificial intelligence, digital technologies and collaboration with world-leading scientists. ZOE’s research has led to over a dozen peer reviewed studies in high impact journals over the last year, including multiple papers in leading science journals such as Nature Medicine. In March 2020 at the onset of the pandemic, the ZOE team felt compelled to help and responded by developing and launching an app in just four sleepless days and nights, built on their existing technologies. The free ZOE Covid Study app, which is a non-profit initiative, now has more than 4.5M users across the UK, US and Sweden, calculating levels of COVID in real-time and sharing anonymous data with researchers across the world. Scientists working with ZOE have published dozens of scientific papers as a result, from understanding COVID symptoms to data on vaccine effectiveness and COVID’s long-term effects. Long-term, ZOE intends to use the app to support wider public health initiatives. About ZOE ZOE is a healthcare science company helping people understand their body’s responses to food. By using machine learning combined with large scale human studies, ZOE is decoding the impact of nutrition on health. ZOE leads the PREDICT Studies and the ZOE COVID Study, which are the world’s largest community powered research programs of their kind in nutrition and COVID-19 respectively. Located in London and Boston, ZOE was founded by Professor Tim Spector of King’s College London, data science leader Jonathan Wolf and entrepreneur George Hadjigeorgiou. ZOE was named one of the Deloitte Fast 50 Rising Stars in 2019 for the company’s contribution to science enabled by technology and machine learning. For more information on ZOE’s mission and science, visit joinzoe.com. Recently Published Nutrition Studies Postprandial glycaemic dips predict appetite and energy intake in healthy individuals, Nature Metabolism,April 12, 2021 Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals, Nature Medicine, January 11, 2021 Human postprandial responses to food and potential for precision nutrition, Nature Medicine, June 11, 2020 About Ahren Innovation Capital Ahren Innovation Capital is an investment institution that supports transformational companies at the intersection of deep tech and deep science that will penetrate, or create, massive markets. Ahren is a unique partnership of investment talent and best-in-class commercial scientists whose technologies are today valued in excess of $100BN combined. Ahren believes in taking asymmetric, considered, risk that will deliver superior rewards – capturing a generational opportunity to provide smart capital to deep technology. With a philosophy espousing the importance of relationships and trust, Ahren provides both patient and active capital to exceptional founders and teams, empowering them to succeed. For more information on Ahren Innovation Capital, visit ahreninnovationcapital.com. Contact Details ZOE Fiana Tulip +1 817-691-3031 fiana@joinzoe.com Company Website https://www.joinzoe.com
May 04, 2021 07:53 AM Eastern Daylight Time
Image
News ReleaseLintbells
With warmer weather upon us, it’s time to get our canine companions safely ready for outdoor exercise. Before including four-legged best friends on a strenuous jaunt, it’s important to thoughtfully work up to it. Veterinarian Dr. Craig Prior, B.V.Sc., C.V.J., member of YuMOVE veterinary advisory board has some simple but important advice for dog owners to minimize injuries and maximize health benefits for you and your dog. Start with a general health checkup - Dogs can’t talk so veterinary expertise is key. A simple wellness check can help to spot issues and address changes that may have taken place over the winter, the pandemic and all of our inactive time at home. Slow and steady wins the race – Be thoughtful about how much you are asking of your dog if they haven’t been that active. Start with short 15-minute neighborhood walks before more strenuous activity. Work your way up to lengthier and more vigorous play and exercise. Look for signs of stiff joints – Walking differently, struggling to stand after lying down or resting, or a reduced desire to play can be signs of stiffness which is common especially as dogs age. A quality supplement can help, but it’s important to do your homework as there are many options out there. Choose one that is clinically proven, offers a money-back guarantee, has quality ingredients and is backed by real science. In addition to glucosamine and chondroitin, look for green-lipped mussels as recent research supports how effective they are for joint health. Be realistic about your dog’s weight –More than half of dogs in the US are obese, according to the Association for Pet Obesity Prevention. Most owners don’t recognize that a healthy dog can look “skinny”. That extra weight makes it more difficult for dogs to get the exercise they need and puts extra strain on their joints. Consult with your veterinarian for a weigh-in and any changes you may need to make in their diet, so exercise doesn’t damage joints. A carefully planned exercise/play routine is crucial to helping get your pets weight back down, especially as we emerge from lockdown. Age matters- As dogs age, they are more at risk for joint problems. This is especially prevalent among larger breeds. This can also be caused by repetitive stress or prior injuries. Be careful about jumping in and out of cars and consider ramps or stairs. Early signs can be hard to notice so it’s important to get your dog checked regularly by a veterinarian. Be patient – Getting back into shape doesn’t happen overnight! Just like humans, each dog will vary in response to losing some unnecessary pounds or getting back into a more vigorous routine. Interviews, additional veterinarian advice and supporting documentation available upon request. For more information on hip/joint health, senior dogs, and keeping pets active for life, please visit https://yumove.com/blogs/health-guides. About YuMOVE YuMOVE, is clinically proven and the #1 hip/joint supplement in the UK now available in the US. YuMOVE is on a mission to keep pets ‘active for life’ which is why they are committed to making the best joint support products in the world. Packed with unique ActivEase® Green Lipped Mussels, sustainably sourced from select New Zealand bays, YuMOVE is full of antioxidants and Omega 3. Its unique premium formula aids joint development supports active joints and structure and promotes mobility. www.yumove.com About Lintbells Lintbells, the UK's #1 Vet Recommended Dog Joint Supplement company, currently helps more than 1 million dogs across Europe and the United States. In March 2019, Lintbells officially entered the US Market with the introduction of their most popular product abroad, YuMOVE Soft Chews. This joint supplement promotes joint and cartilage health in dogs of all breeds and sizes. Made from all-natural, human-grade, non-GMO ingredients, the secret to YuMOVE Soft Chews' success comes from Lintbells own ActivEase® Green Lipped Mussel (or GLM). GLM, a superfood derived from the purest sources in New Zealand, is an essential ingredient with extraordinary properties that improves joint function, mobility, and reduces discomfort in our dogs. This unique ingredient, rich with more Omega 3s than any other GLM, is naturally anti-inflammatory, meaning dogs' stiff joints are eased naturally. Contact Details The Impetus Agency Jamie Baxter +1 775-322-4022 jamie@theimpetusagency.com Company Website https://yumove.com/
May 03, 2021 06:20 AM Eastern Daylight Time
News ReleaseYouth Opportunity Foundation
Indianapolis-based Youth Opportunity Foundation (YOF) announced today that in partnership with the Florida Department of Juvenile Justice (FDJJ) it has been awarded a three year, $1.5M, Second Chance Act grant from the Department of Justice to reduce recidivism for justice-involved youth impacted by traumatic brain injury (TBI). “The prevalence of traumatic brain injury among justice-involved youth is misunderstood, undiagnosed, and thus untreated”, said Denny Armington, YOF President. “We are hopeful that this study will confirm the suspected significant prevalence of TBI among these youth, demonstrate the results of proper brain injury-specific treatment, and provide positive, long term outcomes for the children and the communities in which they live”. Under the supervision of FDJJ, and in concert with the University of South Florida and the Florida Department of Education’s Division of Vocational Rehabilitation (FLVR), YOF will subcontract with Youth Opportunity Investments (YOI), and prominent neuropsychology and neurorehabilitation experts to create a full range of services committed to youth with TBI. Managed by the YOF Advisory Council, the grant will enable the utilization of evidence-based TBI assessment and treatment modalities for youth during their stay in a residential treatment program, and for up to two years after transition to their communities. “Recidivism is a major issue for all juvenile justice programs”, noted Michael Baglivio a criminologist and YOF Advisory Council member. “Without targeted treatment, practitioners run the risk of wasting dollars, negatively impacting public safety, and, most importantly, limiting a youth’s future potential”. In order to accomplish the goals suggested by FDJJ to “reduce recidivism” and “create a full range of services focused on youth with traumatic brain injury”, YOF grant staff will coordinate with four YOI managed Florida facilities in Brooksville, Broward, Kissimmee, and Ocala, statewide brain injury advocacy and support programs, and vocational counselors from FLVR. The post-discharge, community re-entry program will continue to provide supported resource facilitation techniques while focusing on post-secondary education and training, job acquisition and career development. “We are particularly excited” commented Allison Flanagan, Director of FLVR, “about how this project could contribute to successful competitive work outcomes for youth with brain injury.” About Youth Opportunity Foundation (YOF) Youth Opportunity Foundation is focused on expanding this work with at-risk and traumatized young people impacted by the “silent epidemic” of traumatic brain injury (CDC). YOF is a 501c3 nonprofit committed to attacking the issues confronting vulnerable kids through improved clinical treatment and strategies, access to post-secondary education, jobs, and mentored relationships. We focus on those in need of a second chance. Contact Details Youth Opportunity Foundation Denny Armington +1 317-281-0424 denny.armington@yofoundation.org Company Website https://yofoundation.org
April 30, 2021 11:15 AM Eastern Daylight Time
News ReleaseW And W Digital, LLC
Executive Producer Jerry Joyner at W And W Digital, LLC, discussed the announcement during a live broadcast from Dallas, Texas on Tuesday, April 27th, 4:20 pm 2021 from their headquarters in Deep Ellum. “The Luck Summit is just what the doctor ordered in many ways, exclaimed Joyner. I think most Texans believe that our lone star state will be the last to pass the legalization for the use of recreational cannabis, but with efforts like Willie Nelson and his team at the Luck Summit, paired with the High Holidays, I believe Texans will get the cannabis relief they need sooner than later. For me, I partake when I can, but there are hundreds of thousands of people that could be managing pain and health issues with cannabis on a daily basis if legalization legislation can be passed down in Austin. It’s a hell of a lot better than opioids.”, added Joyner. The multi-day virtual summit, seeks to destigmatize, educate, and promote cannabis culture in an informative and entertaining way. During the summit, Luck Presents and cannabis advocates will discuss the plant from a political, ethics, economic, wellness, community, industry and science point of view. Planting the Seed is the marque event of Luck’s “High Holidays”, a 9 day celebration of the cannabis plant and it’s many benefits which began on 4/20 and ends on Willie’s birthday, 4/29. Additionally, Luck Presents is petitioning the Biden Administration and Congress to make 4/20 to 4/29 the “High Holidays” in honor of the cannabis industry and to celebrate Willie’s birthday. “If you haven’t seen Willie Nelson’s letter to President Joe Biden petitioning for the High Holidays, you should and here it is”, added Joyner. The on-line petition can be found here. Weed And Whiskey News is a content distribution studio focusing on Cannabis, Whiskey, Music and the culture within. Their website, live streaming portal and social channels have developed series content including: Infused Kitchen, Miracles of Marijuana, Sips and Quips and The Green Room with Jimmy Vivino. The Green Room with Jimmy Vivino is a weekly Zoom-Cast talk show featuring host and guitar legend Jimmy Vivino and weekly special guests including celebrities, musicians, power house producers, iconic promoters, prolific writers and legendary comedians. Weed And Whiskey TV is an On-Demand TV Network, featuring original, highly-entertaining cannabis and spirit friendly programming. The vast majority of their original programming is only four minutes and 20 seconds in length and can be viewed on virtually any mobile device. Weed and Whiskey TV also streams curated music concerts, feature films, shows and Holiday specials. Twist one up, pour a whiskey...sit back, relax and enjoy Weed And Whiskey TV. It's TV with a Twist! W And W Digital, LLC is an entertainment and media holding concern headquartered in Dallas, Texas. W And W Digital owns and operates the streaming TV Network, Weed And Whiskey TV. In addition to licensed feature films and episodic series, W And W Digital created and produces the following episodic series. “DI High”, “Higher Than Space”, “History Written in Stoned,” “In Luck” (filmed at Willie Nelson’s Luck Reunion that coincides with SXSW), “Paper Bartender”, “Trailer Talks”, “Tequila Shots” and recently launched Weed And Whiskey News.com. Contact Details Weed And Whiskey News Jerry Joyner +1 214-762-7101 info@weedandwhiskeynews.com Company Website https://www.weedandwhiskeynews.com
April 28, 2021 08:45 AM Eastern Daylight Time
Image
News ReleaseNRGene
Enzootic Genetics & Innovation, NRGene and Ben-Gurion University of the Negev will create a new technological consortium to apply the latest genomic selection technologies developed by NRGene for the enhancement of Enzootic’s freshwater shrimp breeding program and performance of its proprietary all-female populations. Enzootic Genetics & Innovation, an animal biotechnology and genetics company leading the all-female freshwater shrimp revolution, and NRGene (TASE: NRGN), an AI based genomic company operating in the agricultural industry, have signed a new technological collaboration agreement. Based on their successful cooperation from 2018 of sequencing and assembling the world’s first high-quality genome of freshwater shrimp M. rosenbergii, the two tech companies, together with researchers from the Life Sciences Department of Ben-Gurion University of the Negev, and the support of the Israel Innovation Authority, will harness NRGene’s novel quantitative genomics breeding tools and algorithms to Enzootic’s genetic selection program. The objective of this collaboration is the selection of superior breeding genetics that will eventually translate into an improvement in yield and revenues for farmers using Enzootic’s all-female freshwater shrimp. “Enzootic assimilates the latest genomic big data tools to accelerate our genetic selection program. Our previous successful collaboration with NRGene, and their pioneering genomic tools, paved the way for this milestone collaboration,” said Managing Director of Enzootic Genetics & Innovation Mr. Amit Hochman. “The continual performance improvement of our all-female population is attributed to data-driven parent populations selection, through Enzootic’s hatcheries in Asia and ultimately the yields of farmers that use this proprietary mono-sex farming strategy.” “Our new collaboration with Enzootic, alongside our past success, is part of NRGene’s strategy to support and enhance breeding of highly important aquaculture species, such as shrimp.” said Dr. Gil Ronen, NRGene’s CEO. “We continuously develop powerful big data analysis tools that navigate genetic selection programs like the one implemented in freshwater shrimp by Enzootic.” “This collaboration, together with academic researchers from Ben-Gurion University of the Negev, creates a unique opportunity to align population quantitative genomic data, with our basic science transcriptomic and metabolic libraries, investigated and studied by our group” said crustacean endocrinologist Prof. Amir Sagi of Ben-Gurion University of the Negev. “This alignment may shed new light on the understanding and regulation of key physiological processes in M. rosenbergii ”. About Enzootic Genetics & Innovation Enzootic Genetics & Innovation is the genetic production arm and R&D center of Enzootic, a Singaporean animal genetic and biotechnology company vertically positioned to support the breeding and farming of all-female freshwater shrimp. Enzootic Genetics & Innovation’s core IP is a cell-based technology that taps into the natural sexual plasticity of shrimp to produce all-female populations, without the use of genetic modification, hormones, or chemicals. Enzootic's proprietary all-female freshwater shrimp populations are produced and supplied to farmers in key territories in Asia through Enzootic's independent hatcheries and nurseries. http://enzootic.com Follow us on LinkedIn About NRGene NRGene develops and commercializes cutting-edge AI based genomic tools that are reshaping agriculture and livestock worldwide. Our cloud-based software solutions are designed to analyze big data generated by next generation sequencing technologies in an affordable, scalable and precise manner. By applying our vast proprietary databases and AI-based technologies, we provide leading international agriculture, seed and food companies, with computational tools to optimize and accelerate their breeding programs. For more information visit www.nrgene.com About Ben Gurion University in the Negev Ben-Gurion University of the Negev (BGU) is the fastest growing research university in Israel, fulfilling the vision of David Ben-Gurion, Israel’s legendary first prime minister, who envisaged the future of Israel emerging from the Negev. The University is at the heart of Beer-Sheva's transformation into an innovation district, where leading multinational corporations and start-ups eagerly leverage BGU’s expertise to generate innovative R&D. BGU effects change, locally, regionally, and internationally. With faculties in Engineering Sciences; Health Sciences; Natural Sciences; Humanities and Social Sciences; Business and Management; and Desert Studies. Contact Details Enzootic Genetics & Innovation Amit Hochman - Managing Director +972 52-389-3796 Amit@enzootic.com NRGene Yana Voldman - Marketing Director +972509002844 yana.voldman@nrgene.com BGU Ehud Zion Waldoks - Deputy Spokesperson, International Media +972546775564 ezw@bgu.ac.il Company Website https://www.nrgene.com
April 28, 2021 08:00 AM Eastern Daylight Time
Image
News ReleaseCIPIO.ai
CIPIO, a B2C Subscription Customer Success company, today announced that Tony Alika Owens and Marge Breya have joined its board of directors and started its seed round. Owens, who previously served as President of Sales Force and Group Vice President of Oracle will be the resident SaaS Growth expert at CIPIO. Having led the launches of multiple Salesforce Portfolio Products, including Einstein, Owens has gathered priceless knowledge on how to roll out and rapidly scale AI-powered SaaS products – a skill that will prove indispensable to CIPIO as it accelerates innovation and growth in the coming months. Breya currently serves as a strategic advisor for 8X8, a leading VoIP solution provider and her leadership in B2B Marketing and Customer Success Strategies for multiple high-growth startups and enterprises will be indispensable in CIPIO’s product roadmap and market expansion. She has extensive B2B GTM and Customer Success expertise spanning over 25 years as a General Manager, Chief Operating Officer, and Chief Marketing Officer – as well as a board veteran – at some of the world’s leading software companies, including SAP, MicroStrategy, Ionic Security, Informatica Corporation, and HP. Breya has also held public company board positions at Jive Software, LSC Communications, and Document Sciences Corporation. “There is no better way for a startup like CIPIO to come out of stealth mode and launch than with a vote of confidence from Tony and Marge,” said Sundeep Sanghavi, Co-Founder and Chairman of CIPIO. “These two powerhouses are proven experts at building, leading, and scaling SaaS companies fast. Their joint decision to invest in CIPIO and kick off our seed round is a strong validation of our team, unique IP, and massive opportunity in one of the fastest growing economies of B2C Subscription.” B2C Subscription Economy is predicted to be @ $478B by 2025 at 68% CAGR, yet its churn rate is double its counterparts in B2B SaaS Economy. CIPIO is uber obsessed with driving growth for B2C Subscription companies through its Domain Infused Data Apps Platform™. “We no longer live in a world where customer lifecycles are linear,” said Owens. “With massive shifts in consumer behavior, B2C Subscription companies need better solutions to minimize churn and boost upsell opportunities. CIPIO’s domain infused Data Apps enables B2C Subscription companies to analyze customer triggers faster, proactively address engagement blindspots and maximize customer impact for repeatable growth and lifetime value.” “CIPIO is determined to bring the power of customer acquisition and retention machine learning to high-churn consumer subscription markets,” said Breya. “Two out of three B2C Subscription companies lack a robust strategy to prevent customer churn. CIPIO’s unique algorithms predict and recommend who, when, what, why, where, and how across mediums and channels enabling B2C Subscription companies to retain customers and drive continuous growth, regardless of transient market dynamics.” About CIPIO: CIPIO is pioneering the Industry's first domain-infused Data Apps Platform™ that humanizes and automates predictions and recommendations to increase Subscriber engagement, retention, and growth for B2C Businesses. CIPIO's early adopters include Crunch Fitness, Industry's Gym, Xponential Fitness, Motor City Church, Pure Barre, Club Pilates, AKT, YogaSix, NCFit, Cyclebar, RowHouse, Stretch Lab, and Stride who have witnessed a significant return on investment in a short time. Contact Details CIPIO Chris Foudy +1 831-238-1905 chris@cipio.ai Company Website https://cipio.ai/
April 27, 2021 01:18 PM Eastern Daylight Time
News ReleaseCortland Biomedical
Cortland Biomedical, a full-service medical textiles product development partner that provides access to a full-spectrum of global engineering, design and manufacturing capabilities, is pleased to announce the addition of three new hires for its esteemed engineering team. Kevin Blatt has been appointed senior manufacturing engineer and will help to support the operations team. For seven years, Kevin has been an influential team member for the Cortland Industrial group with a prominent engineering role in custom braided and cabled synthetic products. He will now transition to Cortland Biomedical. Kevin holds a Bachelor of Science in mechanical engineering technology from the State University of New York Institute of Technology. Ed Tierney and Remington Scott both join the company as process engineers supporting the new product development engineering team. Ed is an engineering professional with over 30 years of experience in the high-performance synthetic fiber industry. Ed holds a Bachelor of Science in mechanical engineering from Lehigh University. He has spent 20+ years in the medical device market and brings experience with ISO 13485 quality management systems. He also brings experience in customer product development, clean room management, and equipment installation and validation. Remington holds a Bachelor of Science in polymer chemistry and Master of Science in textile engineering from North Carolina State University. He started his career with The American Association of Textile Chemists and Colorists (AATCC) gaining experience in textile test method development. Prior to joining Cortland, Remington held the role of Patent Examiner for the United States Patent and Trademark Office (USPTO). “Cortland Biomedical strives to drive a shift in the textile industry by supporting practices conducive to true innovation and bridging the gap between medical device OEMs and textile manufacturers,” said Eric Brown, Director of Operations, Cortland Biomedical. “Building a team of top-notch engineers not willing to settle for the status quo is pivotal to our mission, and we are thrilled to welcome Kevin, Ed and Remington, who we know will all be great assets to our company and our customers.” Last month, Cortland Biomedical completed the transition to a state-of-the-art manufacturing facility strategically designed by textile engineers. Cortland Biomedical’s new facility has certified clean room manufacturing areas - with ISO Class 8 clean rooms for fabric formation and ISO Class 7 clean rooms for assembly, scouring and post-processing. The company, which has continued to invest in the latest knitting, braiding and weaving technologies that ensure its products meet or exceed the design criteria established up-front by its customers, is continuing to seek the brightest engineering and technical talent from across the industry. See available positions here. About Cortland Biomedical Cortland Biomedical custom designs and manufactures high-performance biomedical textile structures leveraging years of experience in medical textile engineering methods including knitting, braiding and weaving. Its thoughtful design concepts challenge the status quo. Cortland Biomedical’s unique combination of advanced equipment and technology, a seasoned medical textile-specific engineering team, and first-rate R&D capabilities allows it to tackle customers’ complex challenges with the innovation and agility expected in the medical device industry. Learn more at cortlandbiomedical.com. Contact Details SVM Public Relations Jordan Bouclin +1 401-490-9700 Jordan.bouclin@svmpr.com
April 27, 2021 10:15 AM Eastern Daylight Time
Contact Us
Pricing
About us
Features
News Hub
Terms of Use
Privacy Policy